Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

Dyne Therapeutics (NASDAQ:DYN) traded higher in the premarket on Wednesday after BMO Capital Markets launched its coverage with an Outperform recommendation and a $50 per share target, citing the ...

BMO Capital analyst Kostas Biliouris initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm ...

He is running in support of several members of his family who live with myotonic dystrophy type 1, a rare genetic condition that causes progressive muscle ...

Age:61 From:Adair, Iowa Previous: Day and Date:Saturday, March 15, 2025 Time:12:30pm-2:00pm Location:Adair Fire Hall Visitation Location: Visitation Day and Date: Visitation Start: Visitation ...

Myotonic dystrophy type 1 (DM1), a genetic disorder, shares overlapping features with chronic kidney disease, including ...

Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025Dosing ...

Thurman M. Wheeler, MD, of the Department of Neurology at Massachusetts General Hospital, is the senior author of a paper published in Nature Communications, "Analysis of human urinary extracellular ...

NEW BRIGHTON, Minn. (WCCO) – A 20-year-old Minnesota man died while embarking on a family trip as part of his final wish. His family spoke about his lasting legacy. Twenty-year-old Giacomo Naylor gave ...

Thurman M. Wheeler, MD, of the Department of Neurology at Massachusetts General Hospital, is the senior author of a paper published in Nature ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...